News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genmab A/S (GEN.CO) Reaches USD 25 Million Milestone In Daratumumab Collaboration With Janssen Biotech Inc. (JNJ)


6/16/2014 11:55:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark; July 7, 2014 – Genmab A/S (OMX: GEN) announced today it has reached the third milestone in its daratumumab collaboration with Janssen Biotech, Inc. (“Janssen”). The USD 25 million milestone payment was triggered by progress in the ongoing Phase III study of daratumumab in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for the treatment of relapsed or refractory multiple myeloma.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES